Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: A Korean cancer study group trial

Acta Oncologica

Volumn 44, Issue 3, 2005, Pages 230-235

  Kim, Tae Won ^a   Kang, Won Ki ^b   Chang, Heung Moon ^a   Park, Joon Oh ^b   Ryoo, Baek Yeol ^c   Ahn, Jin Seok ^d   Zang, Dae Young ^d   Lee, Kyung Hee ^e   Kang, Yoon Koo ^a   Kim, Sung Rok ^f   Kim, Hoon Kyo ^g  

^a University of Ulsan College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Korea Cancer Center Hospital   (South Korea)

^d Hallym University College of Medicine   (South Korea)

^e Yeungnam University College of Medicine   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CAPECITABINE; DEXAMETHASONE; IRINOTECAN; LOPERAMIDE; SEROTONIN ANTAGONIST;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOUTH KOREA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DEOXYCYTIDINE; DIARRHEA; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE I; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PRODRUGS; RECTAL NEOPLASMS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 21344466292     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510029590     Document Type: Article

References (25)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. Lyon: IARCPress; 2001.
2. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997;80:1179-87.
3. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
4. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001;19:4097-106.
5. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14:709-15.
6. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15: 251-60.
7. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
8. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-7.
9. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001;19:3801-7.
10. Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001;37:597-604.
11. Cao S, Hapke G, Rustum YM. Enhanced antitumor activity of xeloda by irinotecan in nude mice bearing human A253 and FaDu head and neck xenografts. Proc Am Assoc Cancer Res 2001;42:464.
12. Kerr DJ, Ten Bokkel Huinink WW, Ferry DR, et al. A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002;21:(abstr 643).
13. Tewes M, Schleucher N, Achterrath W, et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: Results of an extended phase I study dagger. Ann Oncol 2003;14:1442-8.
14. Grothey A, Jordan K, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2003; 22:225(abstr 1022).
15. Bajetta E, Di Bartolomeo M, Mariani L, et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004;100:279-87.
16. Patt YZ, Lin E, Leibmann J, et al. Capecitabine plus irinotecan for chemotherapy-naive patients with metastatic colorectal cancer (MCRC): US multicenter phase II trial. Proc Am Soc Clin Oncol 2003;22:281(abstr 1130).
17. Borner MM, Dietrich D, Popescu R, et al. The impact of the irinotecan (IRI) schedule on efficacy and toxicity of the combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research. Proc Am Soc Clin Oncol GI Symphosium 2004:(abstr 194).
18. Burris HA, Kalman L, Bertoli L, et al. Continuous flat-dose capecitabine plus weekly irinotecan:An alternative first-line treatment for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol GI Symphosium 2004:(abstr 229).
19. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
21. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
22. Tournigand C, Andre T, Achille E, et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-37.
23. Kehrer DF, Sparreboom A, Verweij J, et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001;7:1136-41.
24. Ikegami T, Ha L, Arimori K, et al. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 2002;62:179-87.
25. Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003; 51:403-6.